XEOMIN 50U powder for injection medication leaflet

M03AX01 botulinum toxin type A • Musculo-skeletal system | Muscle relaxants, peripherally acting agents | Other muscle relaxants, peripherally acting agents

Botulinum toxin type A is a neurotoxin produced by the bacterium Clostridium botulinum, widely used for both therapeutic and cosmetic purposes. In medicine, it is indicated for the treatment of cervical dystonia, spasticity, chronic migraines, hyperhidrosis, and other conditions associated with excessive muscle activity.

Botulinum toxin type A works by blocking the release of acetylcholine at the neuromuscular junction, leading to muscle relaxation. It is administered via local injections, with effects typically appearing within a few days and lasting between 3 and 6 months, depending on the indication.

Common side effects include injection site pain, localized muscle weakness, headache, and flu-like symptoms. In rare cases, severe adverse reactions such as difficulty breathing or swallowing may occur. It is essential that treatment is performed by a qualified specialist to minimize risks.

Botulinum toxin type A is a versatile and effective therapeutic option, contributing to symptom relief and improved quality of life for patients.

General data about XEOMIN 50U

Substance: botulinum toxin type A

Date of last drug list: 01-05-2020

Commercial code: W60613007

Concentration: 50U

Pharmaceutical form: powder for injection

Quantity: 6

Product type: original

Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

Manufacturer: MERZ PHARMA GMBH & CO. KGAA - GERMANIA

Holder: MERZ PHARMACEUTICALS GMBH - GERMANIA

Number: 9296/2016/07

Shelf life: 3 years-after packing for marketing;after reconstitution-it is used immediately

Pharmaceutical forms available for botulinum toxin type A

Concentrations available for botulinum toxin type A

100U, 125U SPEYWOOD, 200U, 200U SPEYWOOD/ml, 4U Allergan/0.1ml, 50 U, 500UI, 50U